# FDA Approves Novel Breast-Specific Stereotactic Radiotherapy Device GammaPod for Early-Stage Breast Cancer

> fda · REPORTED · 2026-08-05

The FDA approved GammaPod, a novel breast-specific stereotactic body radiotherapy device, as a treatment for patients with early-stage breast cancer, based on clinical study data. The device is designed specifically to immobilize and precisely target breast tissue during radiation treatment.

About GammaPod — Xcorporeal / Radiotherapy Device Maker: GammaPod is a breast-specific stereotactic body radiotherapy system designed to deliver precise, targeted radiation to early-stage breast cancer tumors while minimizing exposure to surrounding healthy tissue.

- Company: GammaPod — Xcorporeal / Radiotherapy Device Maker
- Sector: medical devices
- Primary source: https://www.oncnursingnews.com/view/stereotactic-radiotherapy-device-approved-by-fda-to-treat-early-stage-breast-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.